PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast by PVI, PeerView Institute for Medical Education
PVI, PeerView Institute for Medical Education
PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
カテゴリー: 科学／医学
マイリストに追加
最後のエピソードを聴く:
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH/AAPA information, and to apply for credit, please visit us at PeerView.com/WBT865. CME/EBAH/AAPA credit will be available until January 25, 2027.
Choices, Changes, and Global Perspectives in CLL Care: Real-World Insights and New Evidence on Finite Therapy With Targeted Agents
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an independent educational grant from AstraZeneca.
Disclosure information is available at the beginning of the video presentation.
前のエピソード
-
1026 - Nicole Lamanna, MD, Lydia Scarfò, MD - Choices, Changes, and Global Perspectives in CLL Care: Real-World Insights and New Evidence on Finite Therapy With Targeted AgentsWed, 4 Feb 2026
-
1025 - Sara A. Hurvitz, MD, FACP - Key Steps to Success With CDK4/6 Inhibition in Early Through Metastatic Breast Cancer: Stratification, Selection, Sequencing, and Specialty ManagementWed, 4 Feb 2026
-
1024 - Jaume Capdevila, MD, PhD - From Poor Prognosis to Emerging Clinical Potential: A Visual Journey of Targeted Therapy Innovation in Extrapulmonary Neuroendocrine CarcinomasWed, 4 Feb 2026
-
1023 - Benjamin C. Creelan, MD - Taking the High Road in NSCLC: Navigating Through Immunotherapy-Based Treatments to Optimize OutcomesWed, 14 Jan 2026
-
1022 - Stephen V. Liu, MD - Innovation Takes the Lead in SCLC: Leveraging Evolving Advances to Drive Improved Outcomes in Limited- and Extensive-Stage DiseaseWed, 14 Jan 2026
-
1021 - Nicola Gökbuget, MD - Moving Forward in B-ALL: Insights on Modern and Emerging Standards With Off-the-Shelf Bispecific AntibodiesWed, 14 Jan 2026
-
1020 - Prof. Solange Peters, MD, PhD / Prof. David Planchard, MD, PhD - The Challenges of Choice in First-Line EGFRm NSCLC: Practical Guidance on Optimising Treatment ApproachesTue, 13 Jan 2026
-
1019 - Sia Daneshmand, MD - Elevating NMIBC Care: Putting the Latest Innovations for Intravesical Therapies Into PracticeTue, 13 Jan 2026
-
1018 - Prof. Eric Van Cutsem, MD, PhD - Precision Tactics With HER2-Targeting ADCs in HER2-Altered Solid Tumors: Candid Conversations and Clinical ConsultsTue, 13 Jan 2026
-
1017 - Komal Jhaveri, MD, FACP - Dialing Up Precision in HR+, HER2- MBC With New Endocrine Agents, Targeted Therapies, and Combinations: A Framework for Multifactorial Clinical DecisionsTue, 13 Jan 2026
-
1016 - Prof. Dr. Max S. Topp, MD - Off the Shelf and in the Clinic for NHL: Leveraging Bispecific Antibody Strategies in DLBCL, FL, and BeyondTue, 13 Jan 2026
-
1015 - Professor John G. Gribben, MD, DSc - Pathways to Personalized Remission in CLL: Leveraging Targeted Standards and Next-Gen Advances for Upfront and Sequential CareTue, 13 Jan 2026
-
1014 - David A. Sallman, MD - Menin Masters for AML Care: Guidance on Integrating Menin Inhibitor Regimens and Boosting Efficacy in Challenging AML SubtypesTue, 13 Jan 2026
-
1013 - Joyce O'Shaughnessy, MD - Forging New Paths With Earlier Use of ADCs in Breast Cancer: From Clinical Breakthroughs to Improved OutcomeTue, 13 Jan 2026
-
1012 - Jennifer Woyach, MD - Revealing New Sequences in CLL: Collaborative Care Planning With Real-World Evidence and Modern TherapeuticsTue, 13 Jan 2026
-
1011 - Zachariah DeFilipp, MD - Rising to the Graft-vs-Host Disease Challenge: Progress in Treatment and Post-HCT Outcomes Across Hematologic CancersTue, 13 Jan 2026
-
1010 - Noel Clarke, MBBS, FRCS ChM / Joaquin Mateo, MD, PhD / Isabela Werneck da Cunha, MD, PhD, MBA - New Kids on the Block in mHSPC: Personalising Approaches Through Emerging Precision TherapiesTue, 13 Jan 2026
-
1009 - Guillermo Garcia-Manero, MD - MASTER MDS for Enhanced Patient Care: Modern Advances With Standard and Emerging Risk-Adapted TreatmentTue, 13 Jan 2026
-
1008 - Sagar Lonial, MD, FACP - Many Roads to Myeloma Remission: Making Sequential Choices With BCMA and Non-BCMA ImmunotherapiesTue, 13 Jan 2026
-
1007 - Prof. Dr. Martin Dreyling - Redrawing Frontlines in MCL: The Upfront Expansion of BTKi Options and Modern Clinical Decision-making in Newly Diagnosed DiseaseTue, 13 Jan 2026
-
1006 - Fred Saad, CQ, MD, FRCS, FCAHS - Innovative Approaches in Prostate Cancer: Bridging Genomics and Patient-Centric TreatmentFri, 9 Jan 2026
-
1005 - Ibiayi Dagogo-Jack, MD, FASCO, Van Karlyle Morris, MD - Calibrating Clinical Approaches for Metastatic Colorectal and Lung Cancers: Insights on Molecular Testing and BRAF Inhibitors in Community SettingsFri, 9 Jan 2026
-
1004 - Barbara Burtness, MD / Ravindra Uppaluri, MD, PhD, FACS - Definitive Innovation in Resectable Head and Neck Cancer: New Immunotherapy Approaches in LA-HNSCCFri, 9 Jan 2026
-
1003 - William D. Tap, MD - Achieving Disease Control in TGCT: Critical Steps For Integrating Evidence-Based Care With CSF1R InhibitorsWed, 31 Dec 2025
-
1002 - Geoffrey Ku, MD - Turning the Tide in Gastric Cancer Management: Integrating Modern Systemic Therapies Across the Disease Continuum for Community-Based CliniciansMon, 29 Dec 2025
-
1001 - Jonathan W. Goldman, MD - Addressing un-MET Needs in NSCLC: Elevating MET-Targeting Options for Patients With a Poor PrognosisMon, 29 Dec 2025
-
1000 - Manmeet S. Ahluwalia, MD, MBA, FASCO - Next-Generation Solutions to Optimize Glioma Care: Applying The Latest Evidence on Molecularly Targeted Therapies in IDH-Mutant DiseaseMon, 29 Dec 2025
-
999 - Prof. Ciro Rinaldi, MD, PhD - Elevating Total Care for PV and ET: From Diagnostic Precision to Patient-Centred InnovationFri, 26 Dec 2025
-
998 - Prof. Dr. Konstanze Döhner - The Practicalities of Personalised Therapy in AML: The Who, How, When, and Why of Treating IDH1-Mutated DiseaseThu, 18 Dec 2025
-
997 - Karen C. Daily, D.O. - RiskReady: A Systems Approach to Improving the Recognition and Treatment of High-Risk, HR+, HER2- Early Breast CancerFri, 12 Dec 2025
-
996 - Lynsey P. Teulings, APRN - Ahead of the Immunotherapy Curve in Head and Neck Cancer: Preparing for Expanding Immune Options in Locally Advanced and Recurrent/Metastatic DiseaseFri, 12 Dec 2025
-
995 - Susana Banerjee, MBBS, MA, FRCP, PhD, Ana Oaknin, MD, PhD - Putting the Puzzle Together in Advanced Ovarian and Cervical Cancers: Translating Evidence Into Practice for Approved and Emerging ADCsFri, 5 Dec 2025
-
994 - Professor Stephen Johnston, MA, FRCP, PhD - Charting New Paths in the Treatment of ER+, HER2- MBC: Seeking Clarity and Consensus Through Evidence-Aligned Clinical CasesWed, 3 Dec 2025
-
993 - Erica L. Mayer, MD, MPH - Nurturing Lasting Benefits of Adjuvant CDK4/6 Inhibitor Therapy in High-Risk HR+, HER2- EBC: Best Practices for Patient Education, AE Monitoring and Management, and Enhanced Adherence/PersistenceWed, 3 Dec 2025
-
992 - Angela Lamarca, MD, PhD, MSc - The Power of Personalised Approaches in Advanced CCA: Team-Based Strategies to Individualise Clinical CareWed, 3 Dec 2025
-
991 - Susana Banerjee, MBBS, MA, FRCP, PhD, Kathleen N. Moore, MD, MS - Harnessing the Power of ADCs in Gynecologic Cancers: Expert Insights for Practice IntegrationWed, 3 Dec 2025
-
990 - Erica L. Mayer, MD, MPH - Risk Assessment and Treatment Initiation: Successfully Jumpstarting the Adjuvant CDK4/6 Inhibitor Treatment Journey in HR+, HER2- EBCWed, 3 Dec 2025
-
989 - Yelena Y. Janjigian, MD*, Siva Raja, MD, PhD, FACS - Critical Conversations for Surgeons and Oncologists in Resectable Gastric/GEJ Cancer: Expert Guidance on Integrating Rapidly Evolving Evidence for Immunotherapy PlatformsThu, 20 Nov 2025
-
988 - Prof. Nicolas Girard, MD, PhD / Pasi A. Jänne, MD, PhD - Making Precision Decisions for Patients With EGFRm NSCLC: Success Strategies With Targeted Options, Potent Combinations, and Emerging AgentsFri, 31 Oct 2025
-
987 - Nikhil I. Khushalani, MD - The Immunotherapy Story Continues for CSCC: Insights and Evidence on Advances in Resectable and Unresectable DiseaseThu, 30 Oct 2025
-
986 - Prof. Sanjay Popat, FRCP, PhD - The Earlier the Better in Lung Cancer: Multispecialty Guidance on Screening, Diagnosis and Management of Resectable NSCLCMon, 27 Oct 2025
-
985 - Paolo Ghia, MD, PhD - The Clock Strikes Innovation in CLL: Upfront Care With Newer, Time-Limited BTKi CombinationsMon, 27 Oct 2025
-
984 - Julie R. Brahmer, MD, MSc, FASCO - Maximizing the Potential and Expanding the Impact of Immunotherapy in Advanced NSCLCFri, 3 Oct 2025
-
983 - Komal Jhaveri, MD, FACP - Visual Exploration of the Evolving Role of Novel Oral SERDs, Other ER-Targeting Therapies, and Rational Combinations in ER+, HER2- MBCFri, 3 Oct 2025
-
982 - Nitin Jain, MD - Committing to Advances for CLL Care: Conversations on Modern Standards of Care and Next-Gen InnovationFri, 3 Oct 2025
-
981 - Komal Jhaveri, MD, FACP - Changing the Scenery in ER+, HER2- MBC With New Oral SERDs and Combinations: Foundations, Evidence, and PracticalitiesFri, 3 Oct 2025
-
980 - Haley A. Moss, MD, MBA / Angeles Alvarez Secord, MD, MHSc - Implementing Immuno-Oncology in Gynecologic Cancer Care for Veterans: Expert Insights on Personalized TreatmentFri, 26 Sep 2025
-
979 - Krish Patel, MD - Mapping Therapeutic Directions in DLBCL: Team Strategies for Prognostic Assessment and Implications for Targeted Therapy and Other Innovative OptionsFri, 26 Sep 2025
-
978 - Tanios Bekaii-Saab, MD - Playing the Right Sequence in mCRC: Practical Strategies for Integrating Multi-Kinase Inhibitors in Later Lines of TherapyFri, 5 Sep 2025
-
977 - Naval Daver, MD, Ghayas Issa, MD - All Rise for Innovation in AML: Processing New Developments With Menin Inhibitors in Challenging AML SubtypesThu, 28 Aug 2025
どのくらいのエピソード
5
